Adjuvant everolimus (EVE) in patients (pts) with completely resected very high-risk renal cell cancer (RCC) and clear cell histology: Results from the phase III SWOG S0931 (EVEREST) trial

Primo N. Lara; Catherine M. Tangen; Elisabeth I. Heath; Matthew Stein; Maxwell V. Meng; A Alva; Sumanta K. Pal; Igor Puzanov; J Clark; Toni K. Choueiri; Neeraj Agarwal; R Uzzo; NB Haas; Melissa Plets; Ulka N. Vaishampayan; Brian Shuch; Ian M. Thompson; Christopher W. Ryan

doi:10.1016/j.annonc.2023.09.1117

Adjuvant everolimus (EVE) in patients (pts) with completely resected very high-risk renal cell cancer (RCC) and clear cell histology: Results from the phase III SWOG S0931 (EVEREST) trial

Primo N. Lara, Catherine M. Tangen, Elisabeth I. Heath, Matthew Stein, Maxwell V. Meng, A Alva, Sumanta K. Pal, Igor Puzanov, J Clark, Toni K. Choueiri, Neeraj Agarwal, R Uzzo, NB Haas, Melissa Plets, Ulka N. Vaishampayan, Brian Shuch, Ian M. Thompson, Christopher W. Ryan

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	American English
Pages (from-to)	S1015-S1015
Number of pages	1
Journal	Annals of Oncology
Volume	34
DOIs	https://doi.org/10.1016/j.annonc.2023.09.1117
State	Published - Oct 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.annonc.2023.09.1117

Cite this

Lara, P. N., Tangen, C. M., Heath, E. I., Stein, M., Meng, M. V., Alva, A., Pal, S. K., Puzanov, I., Clark, J., Choueiri, T. K., Agarwal, N., Uzzo, R., Haas, NB., Plets, M., Vaishampayan, U. N., Shuch, B., Thompson, I. M., & Ryan, C. W. (2023). Adjuvant everolimus (EVE) in patients (pts) with completely resected very high-risk renal cell cancer (RCC) and clear cell histology: Results from the phase III SWOG S0931 (EVEREST) trial. Annals of Oncology, 34, S1015-S1015. https://doi.org/10.1016/j.annonc.2023.09.1117

@article{2a96ade72f98461dba8ed2ff22c0cc38,

title = "Adjuvant everolimus (EVE) in patients (pts) with completely resected very high-risk renal cell cancer (RCC) and clear cell histology: Results from the phase III SWOG S0931 (EVEREST) trial",

author = "Lara, {Primo N.} and Tangen, {Catherine M.} and Heath, {Elisabeth I.} and Matthew Stein and Meng, {Maxwell V.} and A Alva and Pal, {Sumanta K.} and Igor Puzanov and J Clark and Choueiri, {Toni K.} and Neeraj Agarwal and R Uzzo and NB Haas and Melissa Plets and Vaishampayan, {Ulka N.} and Brian Shuch and Thompson, {Ian M.} and Ryan, {Christopher W.}",

year = "2023",

month = oct,

doi = "10.1016/j.annonc.2023.09.1117",

language = "American English",

volume = "34",

pages = "S1015--S1015",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd.",

}

Lara, PN, Tangen, CM, Heath, EI, Stein, M, Meng, MV, Alva, A, Pal, SK, Puzanov, I, Clark, J, Choueiri, TK, Agarwal, N, Uzzo, R, Haas, NB, Plets, M, Vaishampayan, UN, Shuch, B, Thompson, IM & Ryan, CW 2023, 'Adjuvant everolimus (EVE) in patients (pts) with completely resected very high-risk renal cell cancer (RCC) and clear cell histology: Results from the phase III SWOG S0931 (EVEREST) trial', Annals of Oncology, vol. 34, pp. S1015-S1015. https://doi.org/10.1016/j.annonc.2023.09.1117

Adjuvant everolimus (EVE) in patients (pts) with completely resected very high-risk renal cell cancer (RCC) and clear cell histology: Results from the phase III SWOG S0931 (EVEREST) trial. / Lara, Primo N.; Tangen, Catherine M.; Heath, Elisabeth I. et al.
In: Annals of Oncology, Vol. 34, 10.2023, p. S1015-S1015.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - Adjuvant everolimus (EVE) in patients (pts) with completely resected very high-risk renal cell cancer (RCC) and clear cell histology

T2 - Results from the phase III SWOG S0931 (EVEREST) trial

AU - Lara, Primo N.

AU - Tangen, Catherine M.

AU - Heath, Elisabeth I.

AU - Stein, Matthew

AU - Meng, Maxwell V.

AU - Alva, A

AU - Pal, Sumanta K.

AU - Puzanov, Igor

AU - Clark, J

AU - Choueiri, Toni K.

AU - Agarwal, Neeraj

AU - Uzzo, R

AU - Haas, NB

AU - Plets, Melissa

AU - Vaishampayan, Ulka N.

AU - Shuch, Brian

AU - Thompson, Ian M.

AU - Ryan, Christopher W.

PY - 2023/10

Y1 - 2023/10

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:001087480202552&DestLinkType=FullRecord&DestApp=WOS

U2 - 10.1016/j.annonc.2023.09.1117

DO - 10.1016/j.annonc.2023.09.1117

M3 - Meeting Abstract

SN - 0923-7534

VL - 34

SP - S1015-S1015

JO - Annals of Oncology

JF - Annals of Oncology

ER -

Adjuvant everolimus (EVE) in patients (pts) with completely resected very high-risk renal cell cancer (RCC) and clear cell histology: Results from the phase III SWOG S0931 (EVEREST) trial

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this